Corona Vaccine - Dispute over royalties - US University sues Biontech
After a dispute over licensing fees, the University of Pennsylvania has filed a lawsuit against German vaccine manufacturer Biontech. The university had notified the company, a Biontech spokesperson said. The issue concerns "non-exclusive rights" to certain U.S. and European patent applications of the university that are used in the Covid-19 vaccine developed by Biontech and Pfizer. Previously, this was reported by German radio station Deutschlandfunk.
There is disagreement over certain contract aspects, Biontech further stated upon request. This primarily concerns the basis for calculating licensing fees for the sales of the vaccine. "For Biontech, mutual respect and fairness are fundamental principles of our cooperations, which is why we have been in discussions with the University of Pennsylvania about licensing fees for over a year," the Biontech spokesperson explained. "We disagree with the University of Pennsylvania's portrayal and will defend our position firmly."
The dispute over licensing fees involves the German vaccine manufacturer Biontech and the University of Pennsylvania. Despite ongoing negotiations for over a year, Biontech finds itself in a lawsuit filed by the University of Pennsylvania.
